Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michal Inbar-Feigenberg

Showing results (21-30 of 47) with videos related to

Pageof 5
Sort By:
Free Radical Research|December 8, 2022
Retrograde response to mitochondrial dysfunctions associated to LOF variations in <i>FLAD1</i> exon 2: unraveling the importance of RFVT2Maria Tolomeo, Guglielmina Chimienti, Martina Lanza, et al.
Molecular Genetics and Metabolism|August 4, 2023
Corrigendum to: Intrathecal idursulfase-IT in patients with neuronopathic mucopolysaccharidosis II: Results from a phase 2/3 randomized studyJoseph Muenzer, Barbara K Burton, Paul Harmatz, et al.
Molecular Genetics and Metabolism|August 12, 2022
Long-term open-label extension study of the safety and efficacy of intrathecal idursulfase-IT in patients with neuronopathic mucopolysaccharidosis IIJoseph Muenzer, Barbara K Burton, Paul Harmatz, et al.
Molecular Genetics and Metabolism|July 30, 2023
Corrigendum to "Long-term open-label extension study of the safety and efficacy of intrathecal idursulfase-IT in patients with neuronopathic mucopolysaccharidosis II"Joseph Muenzer, Barbara K Burton, Paul Harmatz, et al.
Molecular Genetics and Metabolism|August 26, 2022
Intrathecal idursulfase-IT in patients with neuronopathic mucopolysaccharidosis II: Results from a phase 2/3 randomized studyJoseph Muenzer, Barbara K Burton, Paul Harmatz, et al.
JIMD Reports|February 25, 2026
Intrathecal idursulfase-IT in children younger than 3 years with neuronopathic mucopolysaccharidosis II in a single-arm, open-label, phase 2/3 substudy and extensionJoseph Muenzer, Barbara K Burton, Paul Harmatz, et al.
Journal of Inherited Metabolic Disease|September 10, 2024
Evaluation of early treatment with intravenous idursulfase and intrathecal idursulfase-IT on cognitive function in siblings with neuronopathic mucopolysaccharidosis IIJoseph Muenzer, Barbara K Burton, Paul Harmatz, et al.
Molecular Genetics and Metabolism|January 3, 2021
Glycerol phenylbutyrate efficacy and safety from an open label study in pediatric patients under 2 months of age with urea cycle disordersNicola Longo, George A Diaz, Uta Lichter-Konecki, et al.
JCI Insight|August 18, 2017
Sustained immune tolerance induction in enzyme replacement therapy-treated CRIM-negative patients with infantile Pompe diseaseZoheb B Kazi, Ankit K Desai, Kathryn L Berrier, et al.
Trials|November 18, 2021
Establishing a core outcome set for mucopolysaccharidoses (MPS) in children: study protocol for a rapid literature review, candidate outcomes survey, and Delphi surveysAlison H Howie, Kylie Tingley, Michal Inbar-Feigenberg, et al.
Pageof 5

Showing results (21-30 of 47) with videos related to

Sort By:
Pageof 5
Free Radical Research|December 8, 2022
Retrograde response to mitochondrial dysfunctions associated to LOF variations in <i>FLAD1</i> exon 2: unraveling the importance of RFVT2Maria Tolomeo, Guglielmina Chimienti, Martina Lanza, et al.
Molecular Genetics and Metabolism|August 4, 2023
Corrigendum to: Intrathecal idursulfase-IT in patients with neuronopathic mucopolysaccharidosis II: Results from a phase 2/3 randomized studyJoseph Muenzer, Barbara K Burton, Paul Harmatz, et al.
Molecular Genetics and Metabolism|August 12, 2022
Long-term open-label extension study of the safety and efficacy of intrathecal idursulfase-IT in patients with neuronopathic mucopolysaccharidosis IIJoseph Muenzer, Barbara K Burton, Paul Harmatz, et al.
Molecular Genetics and Metabolism|July 30, 2023
Corrigendum to "Long-term open-label extension study of the safety and efficacy of intrathecal idursulfase-IT in patients with neuronopathic mucopolysaccharidosis II"Joseph Muenzer, Barbara K Burton, Paul Harmatz, et al.
Molecular Genetics and Metabolism|August 26, 2022
Intrathecal idursulfase-IT in patients with neuronopathic mucopolysaccharidosis II: Results from a phase 2/3 randomized studyJoseph Muenzer, Barbara K Burton, Paul Harmatz, et al.
JIMD Reports|February 25, 2026
Intrathecal idursulfase-IT in children younger than 3 years with neuronopathic mucopolysaccharidosis II in a single-arm, open-label, phase 2/3 substudy and extensionJoseph Muenzer, Barbara K Burton, Paul Harmatz, et al.
Journal of Inherited Metabolic Disease|September 10, 2024
Evaluation of early treatment with intravenous idursulfase and intrathecal idursulfase-IT on cognitive function in siblings with neuronopathic mucopolysaccharidosis IIJoseph Muenzer, Barbara K Burton, Paul Harmatz, et al.
Molecular Genetics and Metabolism|January 3, 2021
Glycerol phenylbutyrate efficacy and safety from an open label study in pediatric patients under 2 months of age with urea cycle disordersNicola Longo, George A Diaz, Uta Lichter-Konecki, et al.
JCI Insight|August 18, 2017
Sustained immune tolerance induction in enzyme replacement therapy-treated CRIM-negative patients with infantile Pompe diseaseZoheb B Kazi, Ankit K Desai, Kathryn L Berrier, et al.
Trials|November 18, 2021
Establishing a core outcome set for mucopolysaccharidoses (MPS) in children: study protocol for a rapid literature review, candidate outcomes survey, and Delphi surveysAlison H Howie, Kylie Tingley, Michal Inbar-Feigenberg, et al.
Pageof 5